Table 4 Baseline clinical characteristics of first 132consecutive study patients from each technique group
Characteristics | Total sample | Implant technique | P value | |
|---|---|---|---|---|
PP | IoP | |||
(n =264) | (n =132) | (n = 132) | ||
Age, years | ||||
Mean (SD) | 67.7 (5.8) | 67.9 (6.0) | 67.4 (5.7) | |
Median | 68.0 | 68.0 | 68.0 | |
Range | 50.0–83.0 | 50.0–83.0 | 52.0–78.0 | |
95% CI | 66.9–68.4 | 66.9–68.9 | 66.4–68.4 | 0.6* |
PSA, ng/ml | ||||
Mean (SD) | 8.2 (3.4) | 8.6 (3.7) | 7.8 (3.1) | |
Median | 7.6 | 7.6 | 7.5 | |
Range | 0.7–20.0 | 0.7–20.0 | 0.8–17.0 | |
95% CI | 7.8–8.6 | 7.9–9.2 | 7.3–8.3 | 0.1* |
PSA, n (%) | ||||
≤ 10 | 201 (76.1) | 94 (71.2) | 107 (81.1) | |
> 10 | 63 (23.9) | 38 (28.8) | 25 (18.9) | 0.06** |
Gleason score, | ||||
Mean (SD) | 5.5 (0.9) | 5.3 (0.9) | 5.7 (0.8) | |
Median | 6.0 | 5.0 | 6.0 | |
Range | 1.0–7.0 | 2.0–7.0 | 1.0–7.0 | |
95% CI | 5.4–5.6 | 5.1–5.4 | 5.6–5.8 | <0.001* |
Gleason score < 7, n (%) | 248 (93.9) | 128 (97) | 120 (90.9) | 0.07** |
Clinical stage, n (%) | ||||
T1-T2a | 225 (90.7) | 113 (89.0) | 112 (92.6) | |
> T2a | 23 (9.3) | 14 (11.0) | 9 (7.4) | 0.3** |
ADT, n (%) | 112 (42.4) | 54 (40.9) | 58 (43.9) | 0.6** |
EBRT, n (%) | 16 (6.1) | 4 (3) | 12 (9.1) | 0.07** |
Follow-up, months | ||||
Mean (SD) | 83.3(39.6) | 80.5 (43.5) | 86.2 (35.2) | |
Median | 84.0 | 83.0 | 95.5 | |
Range | 3.0–155.0 | 3.0–155.0 | 7.0–132.0 | |
95% CI | 78.5–88.1 | 72.9–87.9 | 80.2–92.3 | 0.4* |